PE-backed Z-Medica names new president and CEO

Z-Medica, which is backed by DW Healthcare Partners, has hired Stephen J. Fanning as president and CEO. Previously, Fanning was the chairman, president and CEO of Solta Medical. Based in Wallingford, Conn., Z-Medical is a maker of blood clotting technology products.


WALLINGFORD, Conn.–(BUSINESS WIRE)–Stephen J. Fanning has been appointed president and chief executive officer of Z-Medica Corporation, a privately held developer of innovative blood clotting technology products based in Wallingford, Connecticut, it was announced here today by Doug Schillinger, Z-Medica’s chairman of the board. Mr. Schillinger is also managing director of DW Healthcare Partners, a leading private equity investment firm and a majority shareholder of Z-Medica.
Mr. Fanning joins the Company after serving as chairman, president and chief executive officer of publicly traded Solta Medical, a global leader in the medical aesthetics market that was acquired by Valeant Pharmaceuticals in January 2014. He joined Solta’s predecessor company, Thermage, Inc. in 2005 as President and CEO and led the Company’s successful initial public offering in 2006. Previously, Mr. Fanning served as President and CEO of publicly traded Ocular Sciences, Inc., from 2001 to 2005 when the company was sold to The Cooper Companies Inc. In addition, Mr. Fanning served in various leadership positions with Johnson & Johnson prior to his appointment at Ocular.
“Z-Medica has emerged as the leader in developing and bringing to market innovative blood clotting technology addressing hemostatis through our QuikClot family of products. Our goal is to accelerate the Company’s growth through a variety of initiatives. Steve brings to our company a long track record of successfully executing growth strategies for healthcare companies and we look forward to his leadership as we move Z-Medica to the next level,” said Mr. Schillinger.
“QuikClot products have been adopted by the US military and are gaining awareness in a variety of healthcare and emergency response settings. We have the ability to increase our growth rate by applying the Company’s unique technology to address unmet medical needs in a significant number of major markets including hospitals, military, first responders, law enforcement, institutional settings and consumer retail outlets. In addition, our leadership in blood clotting technology creates the opportunity to expand our platform with our current and potential customer base. I am excited about the Z-Medica opportunity and working with the entire team to capitalize on our potential,” said Mr. Fanning.
Mr. Fanning holds a Bachelor of Science degree from Philadelphia University. In addition, he is a member of the board of directors of Syneron Medical LTD, SynergEyes, and Johns Hopkins University School of Nursing Advisory Council.
About Z-Medica® Corporation
Z-Medica Corporation is a medical device company founded in 2002 developing fast acting, easy to use, hemostasis products that stop bleeding wherever it occurs, making it possible to save lives and improve patient outcomes. Based on tests conducted by the Naval Medical Research Center and the U.S. Army Institute for Surgical Research, the Committee on Tactical Combat Casualty Care (CoTCCC) recommended QuikClot Combat Gauze® as the hemostatic agent for the Department of Defense and for use by all U.S. military forces as the first line treatment of traumatic bleeding. QuikClot products are developed and manufactured in the United States. Z-Medica Corporation is a privately-held company based in Wallingford, CT. For more information, visit